To date, there has been limited knowledge regarding the clinical features of pediatric Sjögren’s syndrome and its impact on quality of life. Because it is rare, it is often diagnosed late, and there is a lack of validated pediatric endpoints. British researchers have now investigated clinical phenotypes, disease activity, symptom burden, and treatment experience.
Autoren
- Jens Dehn
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- Genetic Kidney Disease: DOUBLE PROTECT Alport
The SGLT-2 inhibitor dapagliflozin as an add-on to RAS blockade
- Case Study: Cystic Fibrosis in Adults
Recurrent Pneumonia as a Manifestation of Cystic Fibrosis
- Long COVID/Fatigue Clinic
An Innovative Approach: Neuroplasticity and Predictive Processing
- T-cell lymphomas
Diagnostic Challenges and New Treatment Options
- Interbrain Synchrony
Two Brains, One Thought
- Atopic Dermatitis in Children and Adults
Topically Applied “Small Molecules”: Janus Kinases or PDE-4 as Targets?
- Dermatomyositis
Glucocorticoids for more than one year
- The Brain and the Motivation to Eat